-
1.Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian cancer. Oncol Lett. 2020 ;19:2713-2720.
Noguchi T, Sakai K, Iwahashi N, Matsuda K, Matsukawa H, Yahata T, Toujima S, Nishio K, Ino K.
-
2.C-Mannosyl tryptophan increases in the plasma of patients with ovarian cancer. Oncology Letters 19: 908-916, 2020.
Iwahashi N, Inai Y, Minakata S, Sakurai S, Manabe S, Ito Y, Ino K, Ihara Y.
-
3.Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing. Sci Rep. 2019 ; 9:10426.
Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, Toujima S, Nishio K, Ino K.
-
4.Short term outcomes of helical tomotherapy during concurrent chemoradiotherapy for advanced cervical cancer. Mol Clin Oncol. 2019 ;10:382-386.
Mabuchi Y, Takiguchi Y, Yahata T, Mizoguchi M, Sasaki N, Ota N, Minami S, Ino K.
-
5.Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci 2019; 110:1279-1292.
Yahata T, Mizoguchi M, Kimura A, Orimo T, Toujima S, Kuninaka Y, Nosaka M, Ishida Y, Sasaki I, Fukuda-Ohta Y, Hemmi H, Iwahashi N, Noguchi T, Kaisho T, Kondo T, Ino K.
-
6.Calreticulin regulates syncytialization through control of the synthesis and transportation of E-cadherin in BeWo cells. Endocrinology 160, 359-374, 2019.
Iwahashi N, Ikezaki M, Matsuzaki I, Yamamoto M, Toujima S, Murata SI, Ihara Y, Ino K.
-
7.Prevention of lipopolysaccharide-induced preterm labor by the lack of CX3CL1-CX3CR1 interaction in mice. PLoS One. 2018 Nov 6;13(11):e0207085.
Mizoguchi M, Ishida Y, Nosaka M, Kimura A, Kuninaka Y, Yahata T, Nanjo S, Toujima S, Minami S, Ino K, Mukaida N, Kondo T.
-
8.A comprehensive gene mutation analysis of liquid biopsy samples from patients with metastatic colorectal cancer to the ovary: A case report. Oncol Lett. 2018 ;16:6431-6436.
Iwahashi N, Sakai K, Noguchi T, Yahata T, Toujima S, Nishio K, Ino K.
-
9.Calreticulin is involved in invasion of human extravillous trophoblasts through functional regulation of integrin β1. Endocrinology. 2017 ;158:3874-3889.
Yamamoto M, Ikezaki M, Toujima S, Iwahashi N, Mizoguchi M, Nanjo S, Minami S, Ihara Y, Ino K.
-
10.Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction. J Obstet Gynaecol Res. 2017; 43 : 1805-1814.
Nanjo S, Minami S, Mizoguchi M, Yamamoto M, Yahata T, Toujima S, Shiro M, Kobayashi A, Muragaki Y, Ino K.
-
11.Usefulness of the primary tumor SUVmax on preoperative FDG-PET/CT as a prognostic indicator for patients with gynecologic cancers. J Clin Obstet Gynecol Infertility 1(2) 1008, 1-4, 2017.
Ino K, Yahata T, Horiuchi Y, Yagi S, Mabuchi Y.
-
12.Rapidly progressing large-cell neuroendocrine carcinoma arising from the uterine corpus: A case report and review of the literature. Mol Clin Oncol. 2017 ;6:881-885.
Kobayashi A, Yahata T, Nanjo S, Mizoguchi M, Yamamoto M, Mabuchi Y, Yagi S, Minami S, Ino K.
-
13.Downregulation of indoleamine 2, 3-dioxygenase expression in the villous stromal endothelial cells of placentas with preeclampsia. J Reprod Immunol 119:54-60, 2017.
Iwahashi N, Yamamoto M, Nanjo S, Toujima S, Minami S, Ino K.
-
14.Prognostic impact of primary tumor SUVmax on preoperative 18F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma. Mol Clin Oncol 5: 467-474, 2016.
Yahata T, Yagi S, Mabuchi Y, Tanizaki Y, Kobayashi A, Yamamoto M, Mizoguchi M, Nanjo S, Shiro M, Ota N, Minami S, Terada M, Ino K.
-
15.Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy. Mol Clin Oncol 5: 216-222, 2016.
Yagi S, Yahata, T, Mabuchi Y, Tanizaki Y, Kobayashi A, Shiro M, Ota N, Minami S, Terada M, Ino K.
-
16.Large uterine pyomyoma in a perimenopausal female: A case report and review of 50 reported cases in the literature. Mol Clin Oncol 5: 527-531, 2016.
Iwahashi N, Mabuchi Y, Shiro M, Yagi S, Minami S, Ino K.
-
17.AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer. Eur J Pharmacol. 2015 ;766: 63-75.
Kobayashi A, Tanizaki Y, Kimura A, Ishida Y, Nosaka M, Toujima S, Kuninaka Y, Minami S, Ino K, Kondo T.
-
18.Clinicopathologic factors of cervical adenocarcinoma stages IB to IIB. Int J Gynecol Cancer. 2015 ;25:1677-1682.
Mabuchi Y, Yahata T, Kobayashi A, Tanizaki Y, Shiro M, Ota N, Yagi S, Minami S, Ino K.
-
19.Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer via inducing immunosuppressive environment. Cancer Sci 105: 966-973, 2014.
Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O, Ino K.
-
20.Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. Int J Gynecol Cancer 24 :454-460, 2014
Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y, Yagi S, Minami S, Terada M, Ino K.
-
21.Role of the immune tolerance-inducing molecule indoleamine 2,3-dioxygenase in gynecologic cancers. J Cancer Sci Ther 2012, 4: S13:1-5.
Ino K, Tanizaki Y, Kobayashi A, Toujima S, Mabuchi Y, Minami S.
-
22.Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr Opin Obstet Gynecol 23:13-18, 2011.
Ino K.
-
23.Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 11:405-411, 2011.
Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y, Yagi S, Minami S, Tanizaki Y, Kobayashi A, Kikkawa F.
-
1.『婦人科癌診療Q&A 一つ上を行く診療の実践』 （鈴木直, 岡本愛光, 井箟一彦編）. 中外医学社, 東京, 2014.
-
2.Ino K. Prevention of cervical cancer: Era of HPV testing and vaccination. In Konishi I ed. Precision Medicine in Gynecology and Obstetrics, pp87-99, Springer, Heidelberg, Germany, 2017.
-
3.井箟一彦. 4絨毛性疾患 2 分子標的治療薬/免疫チェックポイント阻害薬. 『婦人科腫瘍治療アップデート』（岡本愛光 編）. P187-194, 中外医学社, 東京, 2020.
-
4.井箟一彦. 絨毛性疾患の発生と病理診断. 『産科婦人科臨床 series collection 5悪性腫瘍 ６章絨毛性疾患』（藤井知行、八重樫伸生 編）. P261-270. 中山書店, 東京, 2020.
-
5.井箟一彦. 絨毛性腫瘍の免疫寛容と標的免疫治療in 『基礎と臨床の両側面からみた胎盤学』（日本胎盤学会編）. p414-419, メジカルビュー社, 東京, 2019.
-
6.井箟一彦、園村哲郎. 13絨毛性疾患. 『JSAWI発 一冊でわかる婦人科腫瘍の画像診断』（片渕秀隆、揖靖 編）. P95-97. 文光堂, 東京, 2019.
-
7.井箟一彦. 20-23絨毛性腫瘍 （婦人科疾患）. 『私の治療2019-20年度版』. p1309-1311. 日本医事新報社, 東京, 2019.
-
8.井箟一彦. 絨毛性疾患trophoblastic disease. 『今日の治療指針2018』（福井次矢ら 編）. P1327-1329, 医学書院, 東京, 2018.
-
9.井箟一彦. 絨毛性疾患trophoblastic disease. 『今日の診断指針第７版』（金澤一郎、永井良三 編）. p1805-1808, 医学書院, 東京, 2015.
-
10.井箟一彦, 谷崎優子. 68.絨毛性疾患の管理. 『婦人科診療ハンドブック』（杉山徹ら 編）. p425-432, 中外医学社, 東京, 2014.
-
11.井箟一彦. 絨毛性疾患trophoblastic disease. 『今日の治療指針2014』（福井次矢ら 編）. p1181-1183, 医学書院, 東京, 2014.
-
12.井箟一彦. 絨毛性疾患（胞状奇胎を含む）. 『産科婦人科疾患最新の治療2013-2015』（吉川史隆ら 編）. p247-249, 南江堂, 東京, 2013.
